Eli Lilly's Tirzepatide Shows Strong Results in New Clinical Trials
Eli Lilly’s drug tirzepatide has become the world’s best-selling compound just four years after its launch, driven by demand for diabetes and obesity treatments. Recent phase 3b trials showed promising results when combining tirzepatide with Taltz to treat plaque psoriasis and psoriatic arthritis in obese patients. The combination therapy led to significantly higher rates of skin clearance and symptom improvement compared to using Taltz alone, along with better metabolic outcomes like glucose control and weight loss. These findings could expand the drug’s use beyond diabetes and obesity into autoimmune disorders, potentially increasing its market reach despite growing competition from new therapies in the GLP-1 space. Eli Lilly is also exploring tirzepatide for other conditions such as Crohn's disease and liver diseases, which may further broaden coverage by health insurers. This expansion could help maintain strong demand even if more weight-loss drugs enter the market.
Tickers: $LLY
Topics: Eli Lilly GLP-1 market psoriasis treatment tirzepatide